Jasper Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jasper Therapeutics, Inc. (Nasdaq: JSPR) on June 20, 2024, covering events occurring on June 17 and June 18, 2024. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Anna French, D.Phil., notified the Board of her intent to resign effective June 18, 2024. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Effective June 18, 2024, the Board appointed Svetlana Lucas, Ph.D., as a Class III director. Dr. Lucas brings extensive experience in business development and strategy from roles at Scribe Therapeutics, Tizona Therapeutics, and Amgen.
- Compensation Arrangement: Upon appointment, Dr. Lucas was granted an option to purchase 15,000 shares of voting common stock at an exercise price of $23.19 per share. The option vests 25% on the one-year anniversary of the grant date, with the remainder vesting monthly thereafter (1/48th per month), contingent on continuous service. She is also entitled to standard cash retainers for Board and committee service.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. It notes that Dr. Lucas has no family relationships with other directors or officers and has not engaged in any reportable related party transactions. An indemnification agreement was executed with Dr. Lucas in the standard form used for other directors.
Key Facts for Investor Verification
- Verify the updated composition of the Board of Directors following the resignation of Dr. French and appointment of Dr. Lucas.
- Review the specific vesting schedule and exercise price ($23.19) of the 15,000 share option granted to Dr. Lucas.
- Confirm the absence of any undisclosed disagreements or related party transactions associated with the director transition.
- Check the press release filed as Exhibit 99.1 for additional context on the appointment.